In particular, overexpression of GSDMB (>60%) in HER2 BC is associated with poor prognosis and reduced response to standard anti-HER2 therapy (trastuzumab), such as an autophagy adapter, which plays a key role in regulating autophagosome maturation through Rab7 -Activation plays. This evidence concerns the gene ERBB2 and breast cancer.